Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92‐Gene Assay

BACKGROUND: Although recent advances in immunotherapy have transformed the treatment landscape for many anatomically defined cancers, these therapies are currently not approved for patients diagnosed with cancer of unknown primary (CUP). Molecular cancer classification using gene expression profilin...

Descripción completa

Detalles Bibliográficos
Autores principales: Raghav, Kanwal, Overman, Michael, Poage, Graham M., Soifer, Harris S., Schnabel, Catherine A., Varadhachary, Gauri R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648339/
https://www.ncbi.nlm.nih.gov/pubmed/32893931
http://dx.doi.org/10.1634/theoncologist.2020-0234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648339/
https://www.ncbi.nlm.nih.gov/pubmed/32893931
http://dx.doi.org/10.1634/theoncologist.2020-0234

Ejemplares similares